Literature DB >> 10085625

Management of phacolytic glaucoma: experience of 135 cases.

A Braganza1, R Thomas, T George, A Mermoud.   

Abstract

We retrospectively analyzed 135 eyes with phacolytic glaucoma. A trabeculectomy was added to standard cataract surgery if symptoms endured for more than seven days, or if preoperative control of intraocular pressure (IOP) with maximal medical treatment was inadequate. In the early postoperative period, IOP was significantly lower in the combined surgery group (89 eyes) compared to the cataract surgery group (46 eyes) (p < 0.001). At 6 months there was no difference in IOP or visual acuity between the two groups. There were no serious complications related to trabeculectomy. It is reasonable to conclude that in eyes with a long duration of phacolytic glaucoma, addition of a trabeculectomy to cataract surgery is safe, prevents postoperative rise in intraocular pressure and decreases the need for systemic hypotensive medications. A randomized trial is on to further address this question.

Entities:  

Mesh:

Year:  1998        PMID: 10085625

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


  3 in total

Review 1.  Management and Visual Outcome in Patients of Lens-induced Glaucomas at a Tertiary Eye Care Hospital in South India.

Authors:  M Sharanabasamma; K Vaibhav
Journal:  J Curr Glaucoma Pract       Date:  2016-08-05

2.  Outcomes and favourable prognostic factors in patients of phacomorphic and phacolytic glaucoma managed by manual small-incision cataract surgery: A retrospective study.

Authors:  Shivkumar Chandrashekharan; Sabyasachi Chakrabarty; Meghana Tanwar; Bharadwaja Madhuvarasu; Mohammed Sithiq Uduman; Rengappa Ramakrishnan
Journal:  Indian J Ophthalmol       Date:  2022-04       Impact factor: 2.969

Review 3.  Lens-induced uveitis: an update.

Authors:  Eleanor Ngwe Nche; Radgonde Amer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-01-06       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.